Biomarker News and Research

RSS

A biomarker is a biological molecule found in blood, other body fluids, or tissues that is a sign of a normal or abnormal process, or of a condition or disease. A biomarker may be used to see how well the body responds to a treatment for a disease or condition. Also called molecular marker and signature molecule.

Solution-based circuit chip for rapid, multiplexed detection of pathogens

Life-threatening bacterial infections cause tens of thousands of deaths every year in North America. Increasingly, many infections are resistant to first-line antibiotics. Unfortunately, current methods of culturing bacteria in the lab can take days to report the specific source of the infection, and even longer to pinpoint the right antibiotic that will clear the infection.

13 Jun 2013

Elevated levels of inflammatory biomarkers in individuals associated with high risk of COPD exacerbations

Simultaneously elevated levels of the biomarkers C-reactive protein, fibrinogen and leukocyte count in individuals with chronic obstructive pulmonary disease (COPD) were associated with increased risk of having exacerbations, even in those with milder COPD and in those without previous exacerbations, according to a study in the June 12 issue of JAMA.

12 Jun 2013

PSMA enzyme could become hallmark of new generation of biomarkers for prostate cancer treatment

No matter where they have hidden, metastatic prostate cancer cells still express some of the same signaling as normal prostate cells; in some cases even more so, as with the PSMA enzyme. Harnessing this enzyme could mean the beginning of a new platform for prostate cancer detection, staging, treatment and post-treatment monitoring, say researchers at the Society of Nuclear Medicine and Molecular Imaging's 2013 Annual Meeting.

12 Jun 2013

Hybrid molecular imaging technique helps doctors identify diabetic foot infection

Researchers are kick-starting better diabetic foot care and promoting reduced radiation dose with a new take on a hybrid molecular imaging technique. By targeting both bone cell activity and immune response and improving imaging data interpretation, doctors can better distinguish diabetic foot infection from another common foot condition that often requires an additional bone-marrow scan for definitive diagnosis, say researchers presenting a study at the Society of Nuclear Medicine and Molecular Imaging's 2013 Annual Meeting.

12 Jun 2013

PET and MR imaging can improve quality of life and survival for advanced breast cancer patients

For patients with advanced breast cancer, positron emission tomography and magnetic resonance imaging can improve quality of life and survival by providing physicians with information on the effectiveness of chemotherapy prior to surgery, say researchers presenting at the 2013 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging.

12 Jun 2013

Pitt chemists find new way to detect and monitor diabetes

Diabetes patients often receive their diagnosis after a series of glucose-related blood tests in hospital settings, and then have to monitor their condition daily through expensive, invasive methods. But what if diabetes could be diagnosed and monitored through cheaper, noninvasive methods?

11 Jun 2013

Sensational proteomics results enabled by Bruker’s new IMPACT HD™ Mass Spectrometer with Novel CaptiveSpray™ nanoBooster Ion Source

At the 61st ASMS conference, Bruker introduces exciting new High-Definition capabilities in proteomics and biomarker research. Patented low-noise Captivespray nanoBooster™ ionization coupled with record high-speed digitization Qq-TOF technology and steered by intelligent acquisition software defines complex samples more sharply than ever before.

10 Jun 2013

Powerful new mass spectrometry systems and solutions for life-science research, clinical research, pharma and applied markets announced by Bruker

At the 61st ASMS Conference on Mass Spectrometry and Allied Topics, Bruker today announced mass spectrometry-based product introductions for life-science and clinical research, for biotech/pharma/CRO customers, as well as for industrial and applied markets. The new mass spectrometry systems and solutions are designed to deliver confident analyses with dramatically enhanced resolution, sensitivity and precision.

10 Jun 2013

New non-invasive test measures methylation of SDC2 gene, detects 87% of colorectal cancer

The average 5-year survival for colorectal cancer (CRC) is less than 10% if metastasis occurs, but can reach 90% if detected early. A new non-invasive test has been developed that measures methylation of the SDC2 gene in tissues and blood sera.

10 Jun 2013

SUNY Downstate to receive grant to advance blood test to predict breast cancer progression

SUNY Downstate Medical Center will receive up to $50,000 from the statewide SUNY Technology Accelerator Fund to advance a blood test to determine breast cancer prognosis.

10 Jun 2013

RXi Pharmaceuticals reports positive results from 2 placebo-controlled double blind studies of RXI-109

RXi Pharmaceuticals Corporation, a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using RNA-targeted technologies, today announced the unblinded results of the first of their 2 placebo-controlled double blind studies in volunteers with their anti-scarring agent RXI-109, a proprietary sd-rxRNA compound that has been shown in vitro and in animals to reduce mRNA for connective tissue growth factor.

6 Jun 2013

Scientists suggest that Oprl1 receptor is altered in mice with PTSD-like symptoms

When injected into mice immediately following a traumatic event, a new drug prevents the animals from developing memory problems and increased anxiety that are indicative of post-traumatic stress disorder.

6 Jun 2013

Stem cells that strongly express WNT3 are biased to develop into cells and tissues, say researchers

According to researchers at Boston Children's Hospital, stem cells that strongly express a gene called WNT3 are biased to develop into cells and tissues including pancreas, liver and bladder.

5 Jun 2013

Study examines link between IL-17F and treatment response to interferon beta-1b in multiple sclerosis patients

A study by Hans-Peter Hartung, M.D., of Heinrich-Heine-Universität, Düsseldoft, Germany, and colleagues examines the association between IL-17F and treatment response to interferon beta-1b among patients with relapsing-remitting multiple sclerosis.

4 Jun 2013

Study brings researchers one step closer to personalized colorectal cancer treatment

MET protein levels correlate strongly with epithelial-mesenchymal transition phenotype, a treatment-resistant type of colorectal cancer and may be used as a surrogate biomarker, according to new research from The University of Texas MD Anderson Cancer Center.

4 Jun 2013

NanoString's Prosigna Breast Cancer Assay can help identify node-positive early-stage breast cancer

NanoString Technologies, Inc., a privately held provider of life science tools for translational research and molecular diagnostic products, today announced new results from the combined data analysis of the Austrian Breast & Colorectal Cancer Study Group 8 (ABCSG-8) and Arimidex, Tamoxifen, Alone or in Combination studies.

From NanoString Technologies 3 Jun 2013

Study shows utility of cfDNA blood tests for breast cancer patients

Researchers from Chronix Biomedical and The University of Texas MD Anderson Cancer Center today announced that results from a pilot study demonstrating the utility of cell-free DNA (cfDNA) blood tests as a companion diagnostic for breast cancer patients are to be reported in a poster presentation titled "Modulation of breast cancer cell-free DNA with surgical resection" (Abstract #11060) at the American Society of Clinical Oncology Annual Meeting (ASCO 2013) being held from May 31 through June 4, 2013 in Chicago. The blood test detects cfDNA that is released into the blood stream by damaged and dying cancer cells.

1 Jun 2013

NanoString Technologies to present clinical study of Prosigna Breast Cancer Assay at ASCO 2013

NanoString Technologies, Inc., a privately held provider of life science tools for translational research and molecular diagnostic products, today announced that a clinical study of the Prosigna Breast Cancer Assay will be presented during the Breast Cancer Oral Abstract Session at the 2013 Annual American Society of Clinical Oncology Meeting on Sunday, June 2.

From NanoString Technologies 1 Jun 2013

Glioblastoma patients treated with bevacizumab have deterioration in neurocognitive function

Many glioblastoma patients treated with bevacizumab (Avastin-) have significant deterioration in neurocognitive function, symptoms and quality of life. Not only that, the changes often predict treatment outcomes, according to new research from The University of Texas MD Anderson Cancer Center.

1 Jun 2013

Researchers discover potential biomarkers to identify patients with head and neck cancer

Researchers from Fox Chase Cancer Center will present data at the 49th Annual Meeting of the American Society of Clinical Oncology on Saturday, June 1, which shows the discovery of potential biomarkers that may be used to identify patients with head and neck cancer whose tumors are unlikely to respond to treatment by the targeted therapy cetuximab-a type of monoclonal antibody.

1 Jun 2013

Biomarker News and Research

Further Reading

Solution-based circuit chip for rapid, multiplexed detection of pathogens

Elevated levels of inflammatory biomarkers in individuals associated with high risk of COPD exacerbations

PSMA enzyme could become hallmark of new generation of biomarkers for prostate cancer treatment

Hybrid molecular imaging technique helps doctors identify diabetic foot infection

PET and MR imaging can improve quality of life and survival for advanced breast cancer patients

Pitt chemists find new way to detect and monitor diabetes

Sensational proteomics results enabled by Bruker’s new IMPACT HD™ Mass Spectrometer with Novel CaptiveSpray™ nanoBooster Ion Source

Powerful new mass spectrometry systems and solutions for life-science research, clinical research, pharma and applied markets announced by Bruker

New non-invasive test measures methylation of SDC2 gene, detects 87% of colorectal cancer

SUNY Downstate to receive grant to advance blood test to predict breast cancer progression

RXi Pharmaceuticals reports positive results from 2 placebo-controlled double blind studies of RXI-109

Scientists suggest that Oprl1 receptor is altered in mice with PTSD-like symptoms

Stem cells that strongly express WNT3 are biased to develop into cells and tissues, say researchers

Study examines link between IL-17F and treatment response to interferon beta-1b in multiple sclerosis patients

Study brings researchers one step closer to personalized colorectal cancer treatment

NanoString's Prosigna Breast Cancer Assay can help identify node-positive early-stage breast cancer

Study shows utility of cfDNA blood tests for breast cancer patients

NanoString Technologies to present clinical study of Prosigna Breast Cancer Assay at ASCO 2013

Glioblastoma patients treated with bevacizumab have deterioration in neurocognitive function

Researchers discover potential biomarkers to identify patients with head and neck cancer

Event guide: 15th World Clinical Biomarkers & CDx Europe eBook

Latest eBooks

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo